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LETTERS TO THE EDITOR
Ventricular Reduction Therapy:
Controlled Clinical Trials Overdue
Laks and Marelli’s article on left ventricular reduction therapy (1)
is an excellent presentation of the state of the art. Although this is
not to criticize the authors, their discussion raises an issue that
should have been considered from the inception of this therapy and
is embodied in the penultimate sentence of the report: “Ultimately,
a randomized trial will be required to evaluate this procedure.” The
case for randomized trials of all new therapies (2,3), including
randomization from Patient no. 1 (4), has already been made on
scientific, ethical and indeed behavioral (5) grounds. I will not
belabor it. Unfortunately, this new radical though promising form
of therapy has the disadvantage of a relapse to the “bad old days”
when surgical therapies were considered immune to scientific trials
(6). Originators of new therapies must realize that from Patient no.
1, they really do not know the results. Therefore, on ethical as well
as scientific grounds, patients should be randomized immediately
to give them a “50/50 chance” not to get the new therapy, which
could always be no better or even worse than existing therapy (4).
Therapeutic innovators cannot know the outcome when they begin
to apply any objectively untested treatment. This also applies to the
“learning curve” in which interventionalists, including surgeons,
become technically better with experience (4). Moreover, in any
randomized trial, truly informed consent (versus advised consent)
would let patients know that the trialists have reasonable hopes,
but cannot promise results. (If they did know, a controlled trial
would become unethical because it would deny half of the patients
treatments the trialists consider to be successful). In randomizing
the first patient, hopeful investigators would have half of the
number of patients at any time, but if they are ethical (i.e., honest)
they may be sparing the other half harmful procedures, particularly
when it cannot be known for whom even an ultimately successful
procedure might be contraindicated and could only be developed
with appropriate denominators (2) (i.e., appropriate comparison
groups). As with so many procedures in the past, “ultimately,” as
stated by the authors (1), a trial may be forced, but with what
explanations will patients be recruited?
Finally, this is the day of “evidence-based-medicine”—mainly
on a basis of randomized, controlled clinical trials. This was
rejected ab initio by the originators of ventricular reduction. After
all, “Science teaches us to doubt, and, in ignorance, to refrain.” In
this admonition from Claude Bernard, the word “ethics” can be
substituted for “science” (7). As always, the scientific case and the
ethical case are the same (3).
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REPLY
We appreciate Dr. Spodick’s letter, which suggests an immediate
need to initiate a controlled trial of partial left ventriculectomy
(PLV). Although we do not wish to agree or disagree on the
timing of such a trial, we would like to address several specific
questions that designing such a study raises.
To justify a controlled clinical trial, one must first establish that
there is uncertainty among experts as to treatment preference for a
given group of patients. This is defined as “equipoise” (1). Effective
equipoise has been described as the exact point when the most
likely results of a proposed trial are thought to be an improvement
sufficient to compensate for the disadvantage of the treatment with
the greatest risk (2). Equipoise implies that we, as a group, have no
rational preference for treatment arm A or B. This collective group
has been further defined to include both physicians and the
patients who are to be enrolled in such a study (3,4). This
condition is essential to ensure an adequate informed consent
protocol that protect patients from harmful therapies (5,6). To
perfectly respect patient autonomy, it has been suggested that
patients should be free to choose either arm of a trial, or the
randomization alternative.
For the purpose of discussion, one can assume that PLV
currently achieves 70% success rates at short-term follow-up in
selected patients. With this as a valuable result, PLV could be
among the available treatments for end-stage congestive heart
failure, although not definitively. This implies a surgical procedure
with its inherent risks, which may then require another operation
(transplantation) later on for many patients. Indeed, this has been
observed in the existing reported results.
Past experience with mechanical assist devices has taught us that
a benefit may occur after surgical technique and technology evolve.
In the early experience, some thought that it was not justified to
bridge critically ill patients with an expensive treatment that would
prolong waiting time for a scarce resource (7). We now know that
implantable left ventricular assist devices (LVADs) can maintain
patients’ physical condition (currently as outpatients in many cases)
so that the few donor hearts that are available are not risked for
patients too sick to tolerate transplant surgery (8). Implantable
LVADs are now being studied as a destination therapy. The
cardiomyoplasty trial, in contrast, demonstrated the difficulties in
systematically offering an operation to patients who were relatively
well treated with maximal outpatient medical treatment (unpub-
lished data). The difference with implantable LVADs is that these
were offered to critically ill status I patients receiving maximal
intravenous therapy who were starting to show signs of end-organ
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